Wednesday, May 14, 2025

Viz.ai Wins 2024 Edison Award™ for Innovation for Second Year in a Row

Related stories

Anaconda Launches Unified AI Platform for Open Source

A Total Economic Impact Study Reveals Organizations Building AI...

Contentsquare Unveils Sense: AI Agent Acting as Analyst

Contentsquare brings together the power of AI, autonomous agents,...

Exabeam and AVANT Partner to Expand AI Security Access

New partnership empowers over 3,000 AVANT Trusted Advisors to...

HUMAIN & NVIDIA to Build AI Factories for Next-Gen Intelligence

NVIDIA and the Kingdom of Saudi Arabia (KSA) have...

Siemens Uses AI to Bridge IC Verification Gap with Questa One

Questa One redefines integrated circuit (IC) verification from a...
spot_imgspot_img

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced that it has been named an Edison Award Winner in the 2024 Edison Awards, for the second year in a row. Viz PE with right ventricle/left ventricle ratio (RV/LV), the company’s AI software solution designed to detect and triage pulmonary embolism (PE) and right heart strain, was recognized in the Cardiovascular & Ophthalmic Innovations category. The prestigious Edison Awards, named after the American inventor Thomas Alva Edison, honor excellence in new product and service development, marketing, design and innovation.

“We are honored to win our second Edison Award for innovation,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai. “When we started Viz.ai, we had a vision that by using artificial intelligence, we could help healthcare systems work smarter and faster, improving patient outcomes and ultimately saving lives. Every year in the United States, pulmonary embolism affects around 900,000 patients.1 The recognition of Viz PE, which has the potential to deliver faster and optimal care for patients with pulmonary embolism, validates our efforts to make this vision a reality.”

Also Read: Cured by Innovaccer Launches AI-Powered Healthcare Experience Platform (HXP) to Fuel Holistic Consumer Experience

Viz PE with automated RV/LV ratio measurement became an FDA-cleared AI-powered solution for the detection of suspected PE and assessment of right heart strain in 2022, in partnership with Avicenna.AI. PE is a serious condition, with untreated acute cases having a mortality rate as high as 30% within one month of diagnosis. Timely detection and triage by a multidisciplinary Pulmonary Embolism Response Team (PERT) are critical for patients. Recent data shows that the Viz PE solution combined with PERT activation significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk.2

All nominations are reviewed by the Edison Awards’ Steering Committee and an executive judging body. The panel is composed of more than 2,000 senior business executives and academics from the fields of product development, design, engineering, science, marketing and education, as well as past winners.

Source: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img